Medindia
Medindia LOGIN REGISTER
Advertisement

ViewRay Announces Conference Call and Webcast of First Quarter 2017

Wednesday, May 10, 2017 General News
Advertisement
Financial Results to be Held on May 15, 2017

CLEVELAND, May 10, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2017 financial results, which will take place on Monday, May 15, 2017 after market close.
Advertisement

ViewRay will hold a conference call on Monday, May 15, 2017 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 12048385. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.
Advertisement

After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 90 days following the call. In addition, a telephonic replay of the call will be available until May 22, 2017. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 12048385.

About ViewRayViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-and-webcast-of-first-quarter-2017-300454964.html

SOURCE ViewRay, Inc.

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close